Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Summary

The purpose of this study is to investigate the safety, immunogenicity and clinical activity of GSK2241658A antigen-specific cancer immunotherapeutic (ASCI) for the treatment of patients with non-operable and progressing metastatic cutaneous melanoma.

Timeline

Start

2011-01-31

Primary completion

2018-04-17

Completion

2018-04-17

Publications

• Background American Joint Committee on Cancer. 2002. Cancer staging manual. Sixth edition. Springer editions.

Drugs

Indications